Genextra

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

EryDel, based in Urbino, has developed a patented technology for drug delivery using red blood cells (erythrocytes). This innovative approach allows for the efficient loading of various therapeutic agents, including drugs and proteins, into red blood cells, enabling their gradual release within the patient's body. This method enhances treatment efficacy while minimizing side effects, particularly beneficial for chronic conditions that typically require daily medication. EryDel's solution has been tested in patients with Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. The company offers comprehensive support for the drug delivery process, including a specialized device called the "Red Cell Loader" and disposable kits. Additionally, EryDel is focused on automating blood processing at the point of care, leveraging the unique properties of erythrocytes to facilitate the treatment of various rare diseases.

EryDel, based in Urbino, has developed a patented technology for drug delivery using red blood cells (erythrocytes). This innovative approach allows for the efficient loading of various therapeutic agents, including drugs and proteins, into red blood cells, enabling their gradual release within the patient's body. This method enhances treatment efficacy while minimizing side effects, particularly beneficial for chronic conditions that typically require daily medication. EryDel's solution has been tested in patients with Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. The company offers comprehensive support for the drug delivery process, including a specialized device called the "Red Cell Loader" and disposable kits. Additionally, EryDel is focused on automating blood processing at the point of care, leveraging the unique properties of erythrocytes to facilitate the treatment of various rare diseases.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.